Supplementary material to article by D. Roblin et al. "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis"

Table SII. Pruritus visual analogue scale (VAS) scores at Weeks 2, 4 and 8 for patient subgroup with pruritus  $VAS \ge 40 \text{ mm}$  at baseline

	CT327 0.05% n=29 Mean (min, max)	CT327 0.1% n=26 Mean (min, max)	CT327 0.5% $n=31$ Mean (min, max)	Vehicle n=22 Mean (min, max)
Baseline Week 2	64.3 (40, 91) 36.7 (0, 91)	64.8 (40, 98) 38.3 (0, 82)	66.3 (40, 100) 41.9 (1, 80)	65.5 (40, 100) 42.5 (0, 100)
Week 4	33.6 (0, 100)	32.4 (0, 83)	37.9 (0, 100)	46.0 (1, 95)
Week 8	27.2 (0, 91)	33.3 (0, 80)	29.9 (0, 100)	49.4 (0, 100)
Change at Week 2	-27.7 (-66, 15)	-26.5(-71, 16)	-24.3 (-70, 26)	-23.0 (-70, 55)
Change at Week 4	-30.7 (-68, 50)	-32.5 (-90, 39)	-28.4 (-70, 20)	-19.5 (-70, 46)
Change at Week 8	-37.1**(-73, 20) p=0.0067	-31.5 (-91, 25) p=0.0523	-36.4* (-95, 20) p=0.0124	-16.1 (-88, 50)
Change at Week 2, %	-44.9 (-100, 26.0)	-41.3 (-100, 30.2)	-36.8 (-98.6, 50.0)	-33.1 (-100, 122.2)
Change at Week 4, %	-49.4 (-100.0, 100.0)	-48.0 (-100.0, 88.6)	-44.0 (-100, 28.8)	-27.0 (-98.2, 102.2)
Change at Week 8, %	-59.2 (-100.0, 33.3)	-43.3 (-100.0, 56.8)	-55.0 (-100.0, 26.8)	-21.2 (-100.0, 111.1)

<sup>\*</sup>*p*<0.02; \*\**p*<0.01.